Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

…deramiocel was slowing the trajectory of cardiac dysfunction in DMD measuredCapricor Therapeutics (NASDAQ: CAPR ) recently submitted its BLA for lead candidate deramiocel for patients with Duchenne muscular dystrophy (DMD) cardiomyopathy. As the company noted in their earnings call:About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any t ...